amazon facebook_32 gplus_32 linkedin_32 pinterest_32 tumblr_32 twitter_32 website_32 youtube_32 email_32 rss_32

MySocialGoodNews is dedicated to sharing news about
social entrepreneurship, impact investing, philanthropy
and corporate social responsibility.

Crowdfunding for Social Good

Devin D. Thorpe

Devin Thorpe

Leonhardt Ventures to Present Heart and Heart Valve Regeneration Technologies at Cardiovascular Research Technologies (CRT) Meeting February 21st in D.C.

Press Release – Santa Monica, California and Salt Lake City, Utah (PR Buzz) — February 20th, 2017 – Leonhardt Ventures a leading developer of breakthrough organ regeneration and support assist technologies today announced that Dr. Leslie Miller their Chief Medical Officer will present at the 20th Annual Cardiovascular Research Technologies (CRT) Conference on Tuesday, February 21st, 2017 at 7:40 a.m. EST and 11:40am EST in the CRT CARDIOVASCULAR INNOVATIONS Showcase – see https://www.eventscribe.com/2017/CRT/aaSpeakerBios.asp

2/21/2017 7:40 AM – 7:48 AM BioLeonhardt Heart Regeneration –
2/21/2017 11:40 AM – 11:46 AM Valvublator Heart Valve Decalcification & Regeneration

Dr. Miller will be highlighting our BioLeonhardt combination bioelectric stimulator + re-fillable micro infusion pump + fifteen component stem cell based composition for heart regeneration. He will also present our Valvublator catheter based technology for decalcifying then regenerating heart valves so patients can keep their own instead of getting an implant – click here https://vimeo.com/174622660 to see Valvublator animation video . He will also show briefly our Second Heart Assist, Inc. technology which complements our BioLeonheart heart regeneration treatment by providing circulatory assist support in the descending aorta – click here to see animation video – https://vimeo.com/183574529

Leonhardt Stent Pump from Calx Stars Business Accelerator on Vimeo.

The BioLeonhardt bioelectric stimulator is designed to release of SDF-1 (stem cell homing), IGF-1, HGF (designed to protect against arrthymia risk), EGF, PDGF, VEGF, eNOS, Activin A+B, Follistatin and Tropoelastin as well as controlling on demand stem cell proliferation and differentiation into beating heart muscle within scar tissue. The fifteen- component heart regeneration composition includes adipose derived cells or bone marrow MSCs, muscle derived stem cells, EPCs, a full cocktail of growth factors, nutrient hydrogel, selected exosomes, selected alkaloids, selected anti-inflammatory agents, cardiac matrix and selected MicroRNAs. Click here to see BioLeonhardt animation video – https://vimeo.com/170229378

BIO-LEONHARDT from Calx Stars Business Accelerator on Vimeo.

ABOUT LEONHARDT VENTURES:

Based in Santa Monica, California Leonhardt Ventures is a leading developer of cardiovascular and organ regeneration, support assist and repair technologies. Our products are designed to regenerate your own organs with a combination of bioelectric stimulation controlled release of 13+ regeneration promoting proteins and repeat delivery via a re-fillable micro infusion pump of a fifteen-component organ regeneration composition. Leonhardt Ventures founded in 1982 led the development of cardiovascular balloon catheters in the 1980s, percutaneous heart valves and stent grafts in the 1990s, cardiovascular genetic tests and organ regeneration technologies in the 2000’s. The team led first-in-man cases for percutaneous aortic aneurysm repair in 1995 and first non-surgical stem cell repair of a human heart in 2001. For additional information please visit: www.leonhardtventures.com

ABOUT BIOLEONHARDT:

BioLeonhardt is focused on the development of a combination implantable bioelectric stimulator + micro infusion pump + multi-component stem cell + growth factor based composition for regenerating damaged hearts. The company is currently completing animal studies at the University of Utah funded by a USTAR Technology Acceleration Grant. See www.bioleonhardt.com

ABOUT VALVUBLATOR:

Valvublator is focused on developing a catheter based device to decalcify and regenerate damaged heart valves. See – http://leonhardtventures.com/valvublator/

ABOUT LEONHARDT’S LAUNCHPADS:

Leonhardt’s Launchpads founded in 2007 is an innovation accelerator founded by Leonhardt Ventures to accelerate the early stage development of startups emanating from its own inventions with a primary focus on organ regeneration and associated supporting technologies. Leonhardt’s Launchpads operates out of locations in Santa Monica and Pasadena, California with Cal-X Stars Business Accelerator, Inc. and in Petaluma, California in association with the University of Northern California Science and Technology Innovation Center (UNC STIC) – http://www.uncm.edu/About_BoardDirectors.php. In November of 2015 they founded Leonhardt’s Launchpads Utah, Inc. in Salt Lake City, Utah to work more closely with University of Utah researchers and other local collaborators. See – http://leonhardtventures.com/leonhardts-launchpads-utah/

ABOUT C.R.T.:

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium – http://www.crtmeeting.org/. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

Source:

https://www.prbuzz.com/technology/411196-leonhardt-ventures-to-present-heart-and-heart-valve-regeneration-technologies-at-cardiovascular-research-technologies-crt-meeting-february-21st-in-d-c.html

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Leonhardt’s Launchpads and Leonhardt Ventures existing and new products, the Company’s progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Leonhardt’s Launchpads operates with a very small staff and limited budget while launching more than 30 startups. Not all web sites and information is able to be kept up to date all the time. If you have any specific questions about accuracy or up to date information please email us with your questions. Leonhardt’s Launchpads technologies (licensable technology platorms – startups) are very early stage and un-proven and thus are deemed very high risk investments not suitable to most. Investing in Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads is limited to verified accredited and sophisticated investors only at this time. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Don't miss any Good News!
Subscribe to news from MySocialGoodNews.com!
* = required field
Content I want:



Find Us On

amazon facebook_32 gplus_32 linkedin_32 pinterest_32 tumblr_32 twitter_32 website_32 youtube_32 email_32 rss_32